1.17  -0.02 (-1.68%)		06-12 16:00
Open: 1.17 High: 1.24 Volume: 607,753		Pre. Close: 1.19 Low: 1.17 Market Cap: 70(M)

Short term
Mid term
Targets	6-month :	1.71	1-year :	1.98
Resists	First :	1.47	Second :	1.7
Pivot price	1.29
Supports	First :	1.1	Second :	0.91
MAs	MA(5) :	1.15	MA(20) :	1.29
	MA(100) :	1.42	MA(250) :	1.54
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	18.4	D(3) :	15.2
RSI	RSI(14): 37.1
52-week	High :	3.07	Low :	0.87

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BMEA ] has closed above bottom band by 19.7%. Bollinger Bands are 19.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.24 - 1.25	1.25 - 1.25
Low:	1.15 - 1.16	1.16 - 1.17
Close:	1.16 - 1.17	1.17 - 1.18

Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.

Fri, 12 Jun 2026
[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan

Fri, 12 Jun 2026
Biomea Fusion (BMEA) director granted 196,299 stock options at $1.15 exercise price - Stock Titan

Fri, 12 Jun 2026
Biomea Fusion (BMEA) director Ray Sumita granted 196,299 stock options - Stock Titan

Fri, 12 Jun 2026
Biomea Fusion (BMEA) director receives 173,711-share stock option grant at $1.15 - Stock Titan

Wed, 10 Jun 2026
BMEA: Directors and auditors were approved by majority vote, with results to be filed with the SEC - TradingView

Mon, 08 Jun 2026
Biomea Fusion, Inc. (BMEA) Presents at American Diabetes Association (ADA) 86th Scientific Sessions - Slideshow - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	72 (M)
Shares Float	67 (M)
Held by Insiders	7.1 (%)
Held by Institutions	38.8 (%)
Shares Short	14,400 (K)
Shares Short P.Month	14,090 (K)

EPS	-0.56
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.25
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-79.4 %
Return on Equity (ttm)	-189.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.88
Qtrly Earnings Growth	0 %
Operating Cash Flow	-56 (M)
Levered Free Cash Flow	-33 (M)

PE Ratio	-2.13
PEG Ratio	0
Price to Book value	4.5
Price to Sales	0
Price to Cash Flow	-1.51

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.